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Patients with refractory temporal lobe epilepsy (TLE) are commonly recruited for investigational nti-epilep- 
tic drug (XAED) studies. However, the long-term outcome of TLE after exposure to XAEDs is poorly docu- 
mented. In this pilot study, we report he USC Epilepsy Center's experience of19 patients with TLE enrolled in 
three XAED trials. The data reinforce that TLE is a drug-resistent epilepsy, and referral of good surgical 
candidates for surgery rather than XAED trials is more likely to result in remission. 
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INTRODUCTION 
Only 20-40% of patients with medically 
refractory partial seizures have a greater than 
50% reduction in seizures after exposure to an 
experimental anti-epileptic drug (XAED) ~-5. 
Fewer yet have a greater than 75% reduction 
in seizure frequency, and recent data indicates 
that remission is rare ~-s. Further, the long- 
term impact of XAEDs on temporal obe epi- 
lepsy (TLE) is unknown because most studies 
report results for partial seizures rather than 
for TLE. In contrast o XAEDs, long-term effi- 
cacy of epilepsy surgery is established. The 
NIH consensus statement cites 5-year surgical 
remission rates of 55-75% for temporal obec- 
tomies 7. Therefore, the low likelihood of 
remission from an XAED has significant impli- 
cations for treatment decisions and XAED re- 
cruitment 7.s. 
In order to begin to understand the efficacy 
of XAEDs in TLE, we report our centre's ex- 
perience with three consecutive XAED trials. 
METHODS 
Since 1990, 27 patients with medically refrac- 
tory seizures were enrolled in one of three 
experimental anti-epileptic drug trials at the 
University of Southern California Epilepsy 
Center. Twenty patients were identified who 
definitely met the criteria for TLE and 19 were 
actually exposed to XAEDs (one patient 
initially randomized to placebo never received 
a drug). The diagnosis of TLE was based on the 
proposed revised classification of epilepsies and 
epileptic syndromes of the International 
League Against Epilepsy 9. Included for 
analysis were patients with simple partial 
(autonomic, psychic, experiential auras or 
dysphasia) and/or complex partial seizures 
characterized by motor arrest, oral alimentary 
automatisms, followed by post-ictal confusion. 
Only patients with EEG abnormalities charac- 
teristic of TLE were included for analysis (ex- 
clusively temporal lobe spikes, temporal sharp 
waves or temporal slow waves). 
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All patients enrolled in experimental drug 
trials since 1990 were included. Two trials 
were randomized ouble-blind placebo con- 
trolled and one was open label. For the double- 
blind studies, outcome was defined as the 
percent reduction from baseline in seizure fre- 
quency at completion of the double-blind treat- 
ment phase (3 or 4 months) and 3 or 6 months 
for the open label study (whichever was longest 
prior to discontinuation from the study). 
Outcome was graded based on a scale similar 
to that used at our center to determine outcome 
after epilepsy surgery. Grade 1 was defined as 
greater than or equal to 75% reduction in seiz- 
ure frequency from baseline, Grade 2 was 
defined as 50-74~ reduction, Grade 3 was 
defined as 25-49~ reduction, and Grade 4 was 
defined as 0-24~ reduction from baseline. 
RESULTS 
Table 1 summarizes the response to an XAED 
in the 19 patients with TLE. Two patients 
Table 1: Efficacy of XAEDs in 19 patients with TLE 
Patient Percent Seizure-free Outcome 
reduction grade 1-4"* 
1 50G No 2 
2 + 13F/, No 4 
3 Discontinued No 4 
from study due 
to side effects 
4 3r~ No 4 
5 + 13G No 4 
6 + 1 lr/, No 4 
7 O~ No 4 
8 38~ No 3 
9 + 109~. No 4 
10 100~ Yes 1 
11 35c~ No 3 
12 25r~ No 3 
13 85~ No 1 
14 46~ No 3 
15 Discontinued No 4 
from study due 
to side effects 
16 0 No 4 
17 Discontinued No 4 
from study due 
to side effects 
18 22~ No 4 
19 15~ No 4 
(11%) were classified as Grade 1 (>75% re- 
duction in seizures), of whom only one (5%) 
became seizure-free. Twelve patients (63%) 
were classified as Grade 4 (less than 25% re- 
duction in seizures). The mean reduction in 
seizure frequency in the group was 17%. The 
mean response grade for the group was 3.3. 
No life-threatening side effects were experi- 
enced after exposure to an XAED. Sixteen 
(84~} were discontinued from the XAED (three 
discontinued due to toxicity, one due to proto- 
col violation, and 12 due to lack of efficacy). 
Three (16c~) continued the XAED in long-term 
follow-up. 
Of the 16 patients who did not continue on a 
XAED, five underwent emporal obectomy. 
All five had a minimum follow-up of 1 year, 
and all had a greater than 75~ reduction in 
seizures {Grade 1). Three of the four are seiz- 
ure-free and one has had a greater than 90% 
reduction in seizures (aura only). Of those who 
did not undergo epilepsy surgery, five were 
under-insured, three were poor candidates due 
to psychiatric disorders or bitemporal epilepsy, 
and the rest were not interested in surgery due 
to fear of morbidity. Even if one excludes from 
analysis those three patients who were poor 
candidates, the difference in outcome between 
surgically treated and those who did not 
undergo surgery is significant (P = 0.01, 
Fisher Exact Test) (Table 2). 
Table 2: Response to surgery vs the XAED 
Surgery No surgery 
Greater than 75c~ reduction 5 2 
Less than 75~ reduction 0 9 
P = 0.01, Fisher Exact Test. 
DISCUSSION 
To our knowledge, this pilot study is the first to 
report the efficacy of XAEDs specifically in 
TLE. These data provide further evidence that 
though possible, it is highly unlikely that a 
patient with TLE will undergo remission after 
exposure to existing XAEDs. This result is 
similar to outcome studies of TLE after conven- 
tional therapy. For example, Currie found that 
of 666 patients with TLE, 60% of those treated 
medically were poorly controlled, compared 
with 70% well controlled with surgery 1°. Prim- 
rose and Ojemann also reported that medical 
management of potential surgical candidates 
is generally ineffective H. In a control group of 
potential surgical candidates, none of 37 
patients treated with best medical manage- 
ment became seizure-free 11. Leading XAED 
studies in refractory partial seizures mirror 
Experimental AEDs and TLE 
Table 3: Efficacy of major experimental anti-epileptic drug trials in partial seizures 
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Drug Author(s} Year N Percent seizure-free Comment 
Vigabatrin French et al. 1993 90 5~ 
Gabapentin Browne et al. 1993 774 None reported 
Zonisamide Leppik et al. 1993 167 4c~ 
Topiramate Fincham et al. 1992 356 None reported 
Lamotrigine Richens and Yuen 1991 92 None reported 
433 had a ~>503 reduction in seizure 
frequency 
Mean reduction of seizure frequency 
= 463 
41% had a ~>503 reduction in seizure 
frequency 
32-523 had a ~>503 reduction 
depending on dose 
27% had a ~>503 reduction; mean 
reduction = 27~ 
this fact (Table 3). Generally, only 20-45% will 
have greater than a 50% reduction in seizure 
frequency 1-5. In the two studies in which seiz- 
ure-free data is available (vigabatrin and zoni- 
samide), only 4-5% of a total of 257 pat ients  
became seizure-free 3'4. 
In contrast, temporal lobectomy in medically 
refractory TLE is highly efficacious ~'s'12. 
Ojemann's group reported that 60% of 92 
patients with TLE had a greater than 75% re- 
duction in seizures over a five-year period 12. 
Walczak et al. reported that 89 of 100 patients 
who underwent temporal lobectomy had a 
greater than 75% reduction in seizure fre- 
quency after at least 2 years, and 63% were 
seizure-free s . In our series of 19 patients, the 
difference in response to surgery compared to 
the XAED was significant. Only 2/19 exposed 
to the XAED had a greater than 75% reduction 
in seizures, vs 5/5 who underwent emporal 
lobectomy. However, not all patients in XAED 
trials with TLE are good surgical candidates. 
Those who go to epilepsy surgery most likely 
represent a select group. Also, many patients 
with TLE are enrolled in XAED trials pre- 
cisely because they are not good surgical candi- 
dates, as was the case with three of our 
patients. In our series, however, 5/11 XAED 
failures did not undergo surgery due to under- 
insurance, suggesting that under-insurance 
and the high cost of epilepsy surgery is one of 
several reasons for enrolment in an XAED 
trial. Further study of this issue in larger 
numbers is needed, and we are in the process of 
pooling data from multiple centres to assess 
the response to epilepsy surgery in those who 
fail XAED trials. 
Clearly, XAED studies play a critical role in 
the development of new drugs, which are 
obviously needed. However, the data from this 
study and from Table 3 should instil caution 
when enroling patients in XAED studies who 
are good surgical candidates. Further, enrol- 
ment of patients with TLE, which is a highly 
drug-resistant epilepsy, may obscure and con- 
found the efficacy of otherwise effective 
XAEDs, which might be effective in other epi- 
lepsies. As for informed consent, patients with 
TLE who are good surgical candidates hould 
be informed that epilepsy surgery, though 
costly and with its own risks, is an accepted 
alternative treatment with long-term 
remission rates of 50-60%. Further, patients 
should be informed that XAEDs may result in 
significant improvement, but less commonly in 
complete remission. 
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